Products & ReviewClinical Diagnostics

SARS-CoV-2 Ag Pool Test

The LumiraDx SARS-CoV-2 Ag Pool Test is a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to 5 individuals suspected of COVID-19 or up to 5 asymptomatic individuals. Used with the LumiraDx Platform the test offers a rapid, scalable and cost-effective screening solution for infectious individuals.

Request Pricing

Receive your quote directly from the manufacturer.

Ease of Use
After Sales Service
Value for Money
Write your own review

Test benefits

  • Quickly and easily scale up testing: Low-cost diagnostic screening solutions
  • Maximize resources: Pooled testing can improve access to testing by significantly reducing resources (tests, operators, instruments) required on a per patient basis
  • Save Time: Pooled testing can result in a 40-60% reduction in testing, allowing for significant savings in both time and cost
  • High sensitivity of up to Ct 33 enables the accurate detection of the majority of infectious patients
  • Easy to implement in point of care settings
    • Room Temperature test strip storage
    • Time to result in 12 minutes
    • Compact and portable instrument with connectivity options
  • Facilitate reopening of work sites, sports, cultural venues and events and travel
    • Regular testing of defined populations e.g. healthcare staff, healthcare facility residents, employees, students
    • One time testing of groups for pre entry or reopening of sites

Product Overview